KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Net: 2009-2024

Historic Receivables - Net for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $405.3 million.

  • Alnylam Pharmaceuticals' Receivables - Net rose 172.65% to $964.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $964.8 million, marking a year-over-year increase of 172.65%. This contributed to the annual value of $405.3 million for FY2024, which is 23.65% up from last year.
  • According to the latest figures from FY2024, Alnylam Pharmaceuticals' Receivables - Net is $405.3 million, which was up 23.65% from $327.8 million recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Receivables - Net high stood at $405.3 million for FY2024, and its period low was $102.4 million during FY2020.
  • In the last 3 years, Alnylam Pharmaceuticals' Receivables - Net had a median value of $327.8 million in 2023 and averaged $323.7 million.
  • Data for Alnylam Pharmaceuticals' Receivables - Net shows a peak YoY skyrocketed of 138.11% (in 2020) over the last 5 years.
  • Alnylam Pharmaceuticals' Receivables - Net (Yearly) stood at $102.4 million in 2020, then soared by 93.89% to $198.6 million in 2021, then increased by 19.84% to $238.0 million in 2022, then spiked by 37.75% to $327.8 million in 2023, then increased by 23.65% to $405.3 million in 2024.